New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. (January 2014)

• Record Type: Journal Article
• Authors: Bravatà, Ivana; Fiorino, Gionata; Allocca, Mariangela; Repici, Alessandro; Danese, Silvio
• Is Part Of: Scandinavian journal of gastroenterology. Volume 50:Number 1(2015)
• Page Start: 113
• Page End: 120
• Publication Date: 2014-01
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.3109/00365521.2014.993700
• Languages: English
• ISSNs: 0036-5521

Abstract

<abstract> <title>Abstract</title> <p>Antitumor necrosis factor α agents have dramatically changed the management of inflammatory bowel disease (IBD). However, a significant proportion of patients does not respond or lose response over time. Hence, there is an urgent need for new molecules, with different mechanisms of action, and with a targeted and more effective approach. These new drugs include either small molecules or biological agents. We describe the three most promising classes of molecules in the field of IBD: anti-adhesion, anti-interleukin 12/23 and anti-Janus Kinases therapies.</p> </abstract>